05:38 AM EDT, 08/28/2025 (MT Newswires) -- Telomir Pharmaceuticals ( TELO ) said late Wednesday that new results have expanded the firm's "understanding" of its lead drug candidate, Telomir-1, an epigenetic therapy influencing DNA methylation pathways in cancer, aging and age-related diseases.

The studies showed Telomir-1 potently inhibits UTX (KDM6A), the company said. Abnormal UTX activity has been linked to silencing of tumor suppressors and inappropriate activation of disease-driving genes.

"By inhibiting UTX, Telomir-1 demonstrated the potential to reset faulty DNA methylation patterns and restore more normal gene regulation," the company added.

Shares of the company surged more than 46% in recent premarket activity Thursday.

Price: 2.16, Change: +0.69, Percent Change: +46.62